Related Experiment Videos
Development of novel monoclonal antibodies for the analysis of functional sites in FGF-2
A A Rege1, R J Bjercke, D Erichsen
1Department of Pharmacology, Texas Biotechnology Corporation, Houston 77030, USA. arege@tbc.com
Abstract:
Fibroblast growth factor 2 (FGF-2) can function as a potent mitogen, as well as a survival factor for a variety of mammalian cell types. The biological effects of FGF-2 are mediated by its interaction with two types of cellular binding sites: (1) high affinity tyrosine kinase receptors; and (2) low affinity heparan sulfate proteoglycans (HSPGs) on the cell surface. Although numerous FGF-2 antibodies have been used previously to analyze its biological actions, few studies have utilized antibodies to analyze domains within FGF-2 involved in its interactions with the two binding sites. In this report, we describe the generation and use of two monoclonal antibodies against human recombinant FGF-2 (254F1 and 256A12) that inhibit FGF-2 function. However, these antibodies appear to target preferentially different domains within the FGF-2 molecule, and therefore differentially influence the interactions of FGF-2 with its low and high affinity receptors. 254F1 is a more effective inhibitor of the high affinity, receptor tyrosine kinase binding site, whereas 256A12 appears to be a better inhibitor of the low affinity, HSPG interactions. We also demonstrate that the two antibodies are potent inhibitors of FGF-2 stimulated vascular cell proliferation, and as such have potential use in the treatment of vascular hyperproliferative diseases.
Insights
New monoclonal antibodies targeting Fibroblast Growth Factor 2 (FGF-2) differentially inhibit its binding to cellular receptors. These antibodies show potential for treating vascular hyperproliferative diseases.
Area of Science:
- Molecular Biology
- Cell Biology
- Immunology
Background:
- Fibroblast Growth Factor 2 (FGF-2) is a key regulator of cell proliferation and survival.
- FGF-2 interacts with high-affinity tyrosine kinase receptors and low-affinity heparan sulfate proteoglycans (HSPGs).
- Understanding FGF-2's interaction domains is crucial for therapeutic development.
Purpose of the Study:
- To generate and characterize monoclonal antibodies against human recombinant FGF-2.
- To investigate how these antibodies differentially affect FGF-2 interactions with its binding sites.
- To assess the therapeutic potential of these antibodies in vascular hyperproliferative diseases.
Main Methods:
- Generation of two monoclonal antibodies (254F1 and 256A12) against human recombinant FGF-2.
- Analysis of antibody binding domains and their impact on FGF-2 receptor interactions.
- Evaluation of antibody efficacy in inhibiting FGF-2-stimulated vascular cell proliferation.
Main Results:
- Antibodies 254F1 and 256A12 inhibit FGF-2 function by targeting distinct domains.
- 254F1 preferentially inhibits high-affinity tyrosine kinase receptor binding.
- 256A12 preferentially inhibits low-affinity HSPG interactions.
- Both antibodies effectively inhibit FGF-2-induced vascular cell proliferation.
Conclusions:
- Novel monoclonal antibodies offer specific inhibition of FGF-2 interactions.
- Differential targeting of FGF-2 binding sites provides new therapeutic avenues.
- These antibodies hold promise for treating vascular hyperproliferative disorders.